Il contenuto di questa pagina richiede una nuova versione di Adobe Flash Player.

Scarica Adobe Flash Player

  • Epidemiology and risk stratification in healthy and sick population
  • Expanding the target population for anti-platelet/coagulation therapy
  • Controversial issues: from clinical studies to real life
  • Sport and cardiac pathologies
  • Nuclear cardiology in CAD and CHF patients
Acute Coronary Syndromes:
  • Management of STEMI and non-STEMI patient
  • Evolving therapies for Acute myocardial Infarction: when PTCA, when stent?
  • Hybrid myocardial revascularization
  • Post-ACS patient's route
  • Anti-thrombotic therapy in STEMI and NSTEMI patient
  • Fibrinolitics, IIb/IIIa inhibitors: a therapy beyond any expectation?
  • New antiplatelet drugs
  • Spinal Cord Stimulation in refractory CAD: the last resource?
Global Cardiovascular Risk Prevention:
  • Global Cardiovascular Risk assessment and prevention
  • Insulin Resistance Syndrome, type 2 Diabetes and Atherosclerosis: an explosive mixture
  • Lipid-lowering therapy: do we need statins for all life long?
  • Role of platelets in the atherosclerosis pathogenesis
  • Drug interaction, gender, age and comorbidities
  • Elderly in cardiology: are all patients to be treated the same way?
  • Rigth pharmacological therapy in fragile patient